The Swiss regulators are of opinion that both UBS Group UBS and Credit Suisse Group CS are required to bolster their liquidity positions. The observation was a result of an analysis conducted on the country’s systemically important banks.
The test results indicated that in case of any emergency or a default event, current liquidity requirements would not be sufficient to weather any downturn.
Per the Banking Act, banks are expected to not require bailing out using taxpayers' money. For this reason, the Federal Council conducts a report every two years to check whether these provisions are in line with the international standards, and how the standards have been implemented abroad.
In this fourth report, the council said that a group with representatives from the Federal Department of Finance (“FDF”), Swiss Financial Market Supervisory Authority and Swiss National Bank has been asked to address how the special, ordinance-level liquidity requirements for systemically important banks might be adjusted.
Also, FDF is expected to present proposals on how incentive systems for systemically important banks could be better anchored in terms of global resolvability.
Following the collapse of Archegos Capital Management in March, both the above mentioned banks were affected majorly.
Losing $5.5 billion, Credit Suisse became the bank that took the biggest hit among its peers. In fact, the loss wiped out almost all of its profits made in the first quarter of 2021. If it had not incurred the Archegos loss, Credit Suisse could have reported one of its best quarterly financial performances in almost a decade.
Banks like Credit Suisse, Nomura NMR, Morgan Stanley, UBS Group, Mitsubishi UFJ Financial Group MUFG and Mizuho Bank were the prime brokers that offered almost $50 billion worth of leverage to Archegos but collectively lost more than $10 billion due to the fallout.
Shares of UBS Group and Credit Suisse have gained 37.8% and 2.1%, respectively, over the past six months compared with 41% growth of the industry it belongs to.
One-Year Price Performance
Image Source: Zacks Investment Research
Both the stocks are currently carrying a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Nomura Holdings Inc ADR (NMR) : Free Stock Analysis Report
UBS Group AG (UBS) : Free Stock Analysis Report
Credit Suisse Group (CS) : Free Stock Analysis Report
Mitsubishi UFJ Financial Group, Inc. (MUFG) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research